BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis

1

Multiple sclerosis is an autoimmune disease affecting the central nervous system, with treatment outcomes improving through targeted immune interventions.
2

Autologous haematopoietic stem cell transplantation (ASCT) has evolved from treating hematological diseases to being used for relapsing-remitting multiple sclerosis.
3

The study compares the efficacy and safety of two conditioning regimens, BEAM/ATG and cyclophosphamide/ATG, for patients with relapsing-remitting multiple sclerosis.
4

Recent advancements in ASCT have led to improved safety and efficacy, particularly with the shift from high-intensity to intermediate-intensity conditioning regimens.
5

The primary endpoints of the study include no evidence of disease activity (NEDA) and treatment-related mortality, assessed over multiple follow-up periods.

1